Annick Moureau

Vaccines R&D
Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Serum immunoglobulin A as a biomarker for respiratory syncytial virus infection in children aged <2 years.

Serum immunoglobulin A as a biomarker for respiratory syncytial virus infection in children aged <2 years.

Journal: ERJ open research

Published: December 05, 2024

Serum and mucosal antibody-mediated protection and identification of asymptomatic respiratory syncytial virus infection in community-dwelling older adults in Europe.

Serum and mucosal antibody-mediated protection and identification of asymptomatic respiratory syncytial virus infection in community-dwelling older adults in Europe.

Journal: Frontiers in immunology

Published: June 13, 2024

Antibody-mediated protection against respiratory syncytial virus in children.

Antibody-mediated protection against respiratory syncytial virus in children.

Journal: European respiratory review : an official journal of the European Respiratory Society

Published: May 17, 2024

Safety and immunogenicity of three dose levels of an investigational, highly purified Vero cell rabies vaccine: A randomized, controlled, observer-blinded, Phase II study with a simulated post-exposure regimen in healthy adults.

Safety and immunogenicity of three dose levels of an investigational, highly purified Vero cell rabies vaccine: A randomized, controlled, observer-blinded, Phase II study with a simulated post-exposure regimen in healthy adults.

Journal: Human vaccines & immunotherapeutics

Published: November 03, 2023

T cells, more than antibodies, may prevent symptoms developing from respiratory syncytial virus infections in older adults.

T cells, more than antibodies, may prevent symptoms developing from respiratory syncytial virus infections in older adults.

Journal: Frontiers in immunology

Published: July 17, 2023

Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax® Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.

Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax® Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.

Journal: Vaccine

Published: May 03, 2023

Take a Swipe at Actinide Bioavailability: Application of a New In Vitro Method.

Take a Swipe at Actinide Bioavailability: Application of a New In Vitro Method.

Journal: Health physics

Published: April 06, 2023

Safety and immunogenicity of a new formulation of a pentavalent DTwP-HepB-Hib vaccine in healthy Indian infants-A randomized study.

Safety and immunogenicity of a new formulation of a pentavalent DTwP-HepB-Hib vaccine in healthy Indian infants-A randomized study.

Journal: PloS one

Published: September 06, 2022

Age distribution of dengue cases in southern Vietnam from 2000 to 2015.

Age distribution of dengue cases in southern Vietnam from 2000 to 2015.

Journal: PLoS neglected tropical diseases

Published: June 17, 2022

Serum-free purified Vero rabies vaccine is safe and immunogenic in children: Results of a randomized phaseII pre-exposure prophylaxis regimen study.

Serum-free purified Vero rabies vaccine is safe and immunogenic in children: Results of a randomized phaseII pre-exposure prophylaxis regimen study.

Journal: Vaccine

Published: February 15, 2022

Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.

Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.

Journal: Vaccine

Published: January 28, 2022

Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study.

Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study.

Journal: Vaccine: X

Published: January 10, 2022

Showing 1-12 of 37

Last Updated: 09/26/2026